Why Pfizer’s Stock Rose Despite Dropping Its Weight Loss Drug
Pfizer's shares rose by 1.5% despite halting development of the weight loss drug danuglipron, showcasing the company's resilience. The S&P 500 fell by 0.2%, contrasting with Pfizer's unexpected stock increase,…